Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale

We recently published 10 Stocks Losing Big. Tharimmune, Inc. (NASDAQ:THAR) is one of the worst performers of Tuesday.

Tharimmune tumbled by 20.75 percent on Tuesday to close at $6.11 apiece as investor sentiment was dampened by a share sale transaction on the same day that saw the company raise as much as $5.35 million in fresh funds.

In a regulatory filing, Tharimmune, Inc. (NASDAQ:THAR) said it entered into a share purchase agreement with certain buyers involving the sale of more than 1.18 million common shares at a price of $4.50 apiece.

Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale

The share sale forms part of a shelf registration statement approved by the Securities and Exchange Commission and became effective on March 24, 2023.

The offering is expected to close tomorrow, Wednesday, subject to customary closing conditions.

Additionally, Tuesday’s drop can be attributed to a profit-taking transaction following Monday’s 63-percent surge.

Tharimmune, Inc. (NASDAQ:THAR) is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology.

While we acknowledge the risk and potential of THAR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than THAR and that has 10,000% upside potential, check out our report about this cheapest AI stock.